SCHEMBL2891360

SCHEMBL2891360

CC(=O)N(C)CCC1CN(Cc2ccc(F)cc2)C(=O)c2c(O)c(=O)n(C(C)C)c(=O)n21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.34
HTT P42858 1/20 0.34
TP53 P04637 1/20 0.33
HMGCR P04035 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
GRM2 Q14416 1/20 0.32
MMP1 P03956 1/20 0.32
MMP13 P45452 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
P2RX3 P56373 2/20 0.31
S1PR1 P21453 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13085834 0.91 TP53 (0.35) HTTTP53HMGCRGRM2MMP1
SCHEMBL2891857 0.90 TP53 (0.39) HTTTP53HMGCRKMT2AMEN1
SCHEMBL4226593 0.90 HTT (0.34) ACHEHTTTP53HMGCRKMT2A
SCHEMBL2890889 0.89 ACHE (0.32) ACHEHTTTP53HMGCRKMT2A
SCHEMBL2900634 0.89 ACHE (0.40) ACHEHTTHMGCRKMT2A
SCHEMBL13094093 0.88 HTT (0.35) HTTTP53HMGCRKMT2AGRM2
SCHEMBL2892030 0.88 P2RX3 (0.33) HTTTP53HMGCRKMT2AMEN1
SCHEMBL2899639 0.87 TP53 (0.36) HTTTP53HMGCRKMT2AP2RX3
SCHEMBL2897940 0.87 PTGS1 (0.32) HTTTP53HMGCRGRM2S1PR1
SCHEMBL2892013 0.86 GAA (0.36) HTTTP53HMGCRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP ACHE 1080/4885HTT 4738/4885TP53 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.